{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:08:39Z","timestamp":1792202919354,"version":"4.4.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) is a predominantly drug-induced disease, with a mortality rate of 15\u201320%, that engages the expertise of multiple disciplines: dermatology, allergy, immunology, clinical pharmacology, burn surgery, ophthalmology, urogynecology, and psychiatry. SJS\/TEN has an incidence of 1\u20135\/million persons per year in the United States, with even higher rates globally. One of the challenges of SJS\/TEN has been developing the research infrastructure and coordination to answer questions capable of transforming clinical care and leading to improved patient outcomes. SJS\/TEN 2021, the third research meeting of its kind, was held as a virtual meeting on August 28\u201329, 2021. The meeting brought together 428 international scientists, in addition to a community of 140 SJS\/TEN survivors and family members. The goal of the meeting was to brainstorm strategies to support the continued growth of an international SJS\/TEN research network, bridging science and the community. The community workshop section of the meeting focused on eight primary themes: mental health, eye care, SJS\/TEN in children, non-drug induced SJS\/TEN, long-term health complications, new advances in mechanisms and basic science, managing long-term scarring, considerations for skin of color, and COVID-19 vaccines. The meeting featured several important updates and identified areas of unmet research and clinical need that will be highlighted in this white paper.<\/jats:p>","DOI":"10.3389\/fmed.2023.1213889","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T07:14:24Z","timestamp":1697008464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Updates in SJS\/TEN: collaboration, innovation, and community"],"prefix":"10.3389","volume":"10","author":[{"given":"Madeline E.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya Krishna","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Beachkofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo R.","family":"Cibotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni P.","family":"Dodiuk-Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grimstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kroshinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe J.","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Martin-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Pakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Palubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena B.","family":"Pasieka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah N.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Shupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhih Yu","family":"Syu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemberlee","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Dewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ezhkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Himed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"McCawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison E.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ostrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schlundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tkaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie J.","family":"Divito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"883121","DOI":"10.3389\/fmed.2022.883121","article-title":"Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Dobry","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study","volume":"23","author":"Gronich","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/jamadermatol.2022.0484","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-coordinating research priorities to move the field forward","volume":"158","author":"Phillips","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jama.2020.25473","article-title":"Race and pharmacogenomics-personalized medicine or misguided practice?","volume":"325","author":"Goodman","year":"2021","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/bjd.20076","article-title":"Professor Jean-Claude Roujeau (1944-2021)","volume":"185","author":"Stern","year":"2021","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus","volume":"185","author":"Bruggen","year":"2021","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jdin.2023.01.012","article-title":"Physical and mental health impact of Stevens-Johnson syndrome\/toxic epidermal necrolysis and post\u2013hospital discharge care: identifying practice gaps","volume":"11","author":"Coromilas","year":"2023","journal-title":"JAAD Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fphar.2020.00969","article-title":"Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions","volume":"11","author":"Chang","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B*13: 01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fphar.2020.00527","article-title":"Usage pattern of carbamazepine and associated severe cutaneous adverse reactions in Singapore following implementation of HLA-B*15:02 genotyping as standard-of-care","volume":"11","author":"Sung","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.5415\/apallergy.2020.10.e36","article-title":"Diagnostic procedures & practices in drug allergy\/hypersensitivity: a survey of 13 Asian countries","volume":"10","author":"Tang","year":"2020","journal-title":"Asia Pac Allergy"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.5415\/apallergy.2020.10.e8","article-title":"Drug hypersensitivity reactions in Asia: regional issues and challenges","volume":"10","author":"Thong","year":"2020","journal-title":"Asia Pac Allergy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in east Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"652091","DOI":"10.3389\/fmed.2021.759559","article-title":"Genetics of severe cutaneous adverse reactions","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-019-0143-8","article-title":"Association of carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients","volume":"20","author":"Capule","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat Commun"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/ijd.15792","article-title":"HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese","volume":"61","author":"Wong","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/17425255.2021.1946514","article-title":"Genotyping HLA alleles to predict the development of severe cutaneous adverse drug reactions (SCARs): state-of-the-art","volume":"17","author":"Jantararoungtong","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/pharmacy8030163","article-title":"Clinical application and educational training for pharmacogenomics","volume":"8","author":"Guy","year":"2020","journal-title":"Pharmacy"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"100399","DOI":"10.1016\/j.dmpk.2021.100399","article-title":"Pharmacogenomics research and its clinical implementation in Thailand: lessons learned from the resource-limited settings","volume":"39","author":"Sukasem","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cpt.1312","article-title":"Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: an evaluation framework","volume":"105","author":"Plumpton","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.5415\/apallergy.2022.12.e17","article-title":"Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a single-center study","volume":"12","author":"Yoo","year":"2022","journal-title":"Asia Pac Allergy"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/ijms18081737","article-title":"In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already?","volume":"18","author":"Porebski","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1076029620950831","DOI":"10.1177\/1076029620950831","article-title":"The role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"27","author":"Sadek","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"187.e1","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.iac.2022.01.003","article-title":"Skin testing approaches for immediate and delayed hypersensitivity reactions","volume":"42","author":"Barbaud","year":"2022","journal-title":"Immunol Allergy Clin N Am"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"573573","DOI":"10.3389\/fphar.2020.573573","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"923991","DOI":"10.3389\/fmed.2022.923991","article-title":"Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions","volume":"9","author":"Copaescu","year":"2022","journal-title":"Front Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaci.2023.03.024","article-title":"In vitro\/ex vivo assays for severe cutaneous drug reactions","volume":"152","author":"Copaescu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1159\/000520494","article-title":"Comparing the accuracy of ABCD-10 and SCORTEN in predicting the in-hospital mortality of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multi-institutional study from Central China","volume":"238","author":"Suo","year":"2022","journal-title":"Dermatology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.07.001","article-title":"Development and validation of a novel score to predict mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis: CRISTEN","author":"Hama","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2133.1991.tb04952.x","article-title":"Measurement of involved surface area in patients with psoriasis","volume":"124","author":"Ramsay","year":"1991","journal-title":"Br J Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jbcr\/iry050","article-title":"Changing the way we think about burn size estimation","volume":"40","author":"Pham","year":"2019","journal-title":"J Burn Care Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/archinte.1915.00070240077005","article-title":"Fifth paper the measurement of the surface area of man","author":"DuBOIS","year":"1915","journal-title":"Arch Intern Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jamasurg.2021.5848","article-title":"Practical computer vision application to compute total body surface area burn: reappraising a fundamental burn injury formula in the modern era","volume":"157","author":"Choi","year":"2022","journal-title":"JAMA Surg"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0305-4179(99)00047-9","article-title":"The inter-rater reliability of estimating the size of burns from various burn area chart drawings","volume":"26","author":"Wachtel","year":"2000","journal-title":"Burns"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.burns.2019.08.014","article-title":"A comparison study of methods for estimation of a burn surface area: Lund and Browder, e-burn and Mersey burns","volume":"46","author":"Chong","year":"2020","journal-title":"Burns"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BCR.0000000000000613","article-title":"Want correct percentage of TBSA burned? Let a layman do the assessment","volume":"39","author":"Tocco-Tussardi","year":"2018","journal-title":"J Burn Care Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/srt.12688","article-title":"Crowdsourcing to delineate skin affected by chronic graft-vs-host disease","volume":"25","author":"Tkaczyk","year":"2019","journal-title":"Skin Res Technol"},{"key":"ref58","first-page":"168","article-title":"Skin lesion analysis toward melanoma detection: A challenge at the 2017 international symposium on biomedical imaging (ISBI), hosted by the international skin imaging collaboration (ISIC)","author":"Codella","year":"2018"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamadermatol.2021.4915","article-title":"Checklist for evaluation of image-based artificial intelligence reports in dermatology: CLEAR Derm consensus guidelines from the international skin imaging collaboration artificial intelligence working group","volume":"158","author":"Daneshjou","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jamadermatol.2023.1347","article-title":"Development of a skin-directed scoring system for Stevens-Johnson syndrome and epidermal necrolysis: a delphi consensus exercise","volume":"159","author":"Waters","year":"2023","journal-title":"JAMA Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/medicina57111157","article-title":"Staphylococcal scalded skin syndrome and bullous impetigo","volume":"57","author":"Brazel","year":"2021","journal-title":"Medicina"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/RHU.0000000000000830","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like lupus erythematosus","volume":"25","author":"Tankunakorn","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-4471-6729-7_24","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","author":"Klimas","year":"2015","journal-title":"Cutaneous Drug Eruptions"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1093\/milmed\/usaa029","article-title":"Erythema multiforme versus Stevens-Johnson syndrome\/toxic epidermal necrolysis: subtle difference in presentation, major difference in management","volume":"185","author":"Newkirk","year":"2020","journal-title":"Mil Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaad.2022.10.035","article-title":"Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort study","volume":"88","author":"Hung","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/liv.14903","article-title":"Allopurinol hepatotoxicity is associated with human leukocyte antigen class I alleles","volume":"41","author":"Fontana","year":"2021","journal-title":"Liver Int"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cpt.1493","article-title":"Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharm Ther"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"adv 00377","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jdcr.2020.03.007","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma","volume":"6","author":"Kwon","year":"2020","journal-title":"JAAD Case Rep"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"898790","DOI":"10.3389\/fmed.2022.898790","article-title":"High grade dermatologic adverse events associated with immune checkpoint blockade for cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16572","article-title":"Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction","author":"Shi","year":"2023","journal-title":"Int J Dermatol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jaad.2018.10.039","article-title":"Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions","volume":"80","author":"Mori","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.19129","article-title":"Treatment of severe cutaneous adverse reaction with tocilizumab","volume":"183","author":"Hibler","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (ir AEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000877","article-title":"Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases","volume":"33","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Melanoma Res"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jaip.2022.04.027","article-title":"Practical implementation of genetics: new concepts in immunogenomics to predict, prevent, and diagnose drug hypersensitivity","volume":"10","author":"Deshpande","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"642012","DOI":"10.3389\/fgene.2021.642012","article-title":"Visual genomics analysis studio as a tool to analyze multiomic data","volume":"12","author":"Hertzman","year":"2021","journal-title":"Front Genet"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"eaaw6142","DOI":"10.1126\/scitranslmed.aaw6142","article-title":"Plasma exosomal mi R-375-3p regulates mitochondria-dependent keratinocyte apoptosis by targeting XIAP in severe drug-induced skin reactions","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"106697","DOI":"10.1016\/j.phrs.2023.106697","article-title":"Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis","volume":"189","author":"Shi","year":"2023","journal-title":"Pharmacol Res"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: the release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"eaax2398","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/bjophthalmol-2021-319302","article-title":"Prognostic significance of matrix metalloproteinase 9 in COMET operated chronic ocular Stevens-Johnson syndrome","volume":"107","author":"Venugopal","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jid.2022.11.024","article-title":"TNF-alpha\u2013mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"143","author":"Olsson-Brown","year":"2022","journal-title":"J Invest Dermatol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","article-title":"T-scan: a genome-wide method for the systematic discovery of T cell epitopes","volume":"178","author":"Kula","year":"2019","journal-title":"Cells"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jbcr\/iraa214","article-title":"An assessment of research priorities to dampen the pendulum swing of burn resuscitation","volume":"42","author":"Burmeister","year":"2021","journal-title":"J Burn Care Res"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e0563","DOI":"10.1097\/MD.0000000000010563","article-title":"Effectiveness of aspiration or deroofing for blister management in patients with burns: a prospective randomized controlled trial","volume":"97","author":"Ro","year":"2018","journal-title":"Medicine"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.295.6591.181","article-title":"Management of blisters in minor burns","volume":"295","author":"Swain","year":"1987","journal-title":"Br Med J"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00000637-199508000-00002","article-title":"Toxic epidermal necrolysis: a review and report of the successful use of biobrane for early wound coverage","volume":"35","author":"Bradley","year":"1995","journal-title":"Ann Plast Surg"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archsurg.1984.01390170097019","article-title":"Improved treatment of the Stevens-Johnson syndrome","volume":"119","author":"Marvin","year":"1984","journal-title":"Arch Surg"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.burns.2016.06.003","article-title":"The use of porcine xenografts in patients with toxic epidermal necrolysis","volume":"42","author":"Young","year":"2016","journal-title":"Burns"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0884533616642746","article-title":"Nutrition in toxic epidermal necrolysis: a multicenter review","volume":"31","author":"Graves","year":"2016","journal-title":"Nutr Clin Pract"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"C58","DOI":"10.1152\/ajpcell.00106.2021","article-title":"Burn-induced hypermetabolism and skeletal muscle dysfunction","volume":"321","author":"Knuth","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.burns.2018.03.009","article-title":"Anabolic and anticatabolic agents used in burn care: what is known and what is yet to be learned","volume":"46","author":"Gus","year":"2020","journal-title":"Burns"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/ICO.0000000000002263","article-title":"Long-term progression of ocular surface disease in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"39","author":"Yoshikawa","year":"2020","journal-title":"Cornea"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ophtha.2011.01.046","article-title":"Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases","volume":"118","author":"Gregory","year":"2011","journal-title":"Ophthalmology"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jtos.2019.03.001","article-title":"Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"17","author":"Shanbhag","year":"2019","journal-title":"Ocul Surf"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jtos.2020.03.004","article-title":"Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"18","author":"Shanbhag","year":"2020","journal-title":"Ocul Surf"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ajo.2019.07.006","article-title":"Long-term effect of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"208","author":"Shanbhag","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2021.06.015","article-title":"Corticosteroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis patients with acute ocular involvement","volume":"231","author":"Mieno","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jtos.2020.05.003","article-title":"The effects of systemic cyclosporine in acute Stevens-Johnson syndrome\/toxic epidermal necrolysis on ocular disease","volume":"19","author":"Hall","year":"2021","journal-title":"Ocul Surf"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"661891","DOI":"10.3389\/fmed.2021.800685","article-title":"Clinical aspects of Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Taiwan","volume":"8","author":"Ma","year":"2021","journal-title":"Front Med"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2019.01.006","article-title":"Prosthetic replacement of the ocular surface ecosystem treatment for ocular surface disease in pediatric patients with Stevens-Johnson syndrome","volume":"201","author":"Wang","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clae.2020.05.007","article-title":"Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Itoi","year":"2020","journal-title":"Cont Lens Anterior Eye"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40123-023-00725-w","article-title":"Ophthalmic aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis: a narrative review","volume":"12","author":"Toth","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijstd.IJSTD_61_19","article-title":"Study of genital manifestations of Stevens Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Gulanikar","year":"2022","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"874445","DOI":"10.3389\/fmed.2022.874445","article-title":"Stevens Johnson syndrome: past, present, and future directions gynecologic manifestations and management in SJS\/TEN","volume":"9","author":"Den Adel","year":"2022","journal-title":"Front Med"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40264-017-0608-0","article-title":"Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"41","author":"Olteanu","year":"2018","journal-title":"Drug Saf"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","article-title":"Long-term follow-up of patients treated for toxic epidermal necrolysis","volume":"27","author":"Oplatek","year":"2006","journal-title":"J Burn Care Res"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"DES80","DOI":"10.1167\/iovs.18-24019","article-title":"Severe dry eye with combined mechanisms is involved in the ocular sequelae of SJS\/TEN at the chronic stage","volume":"59","author":"Sotozono","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1468-3083.2012.04667.x","article-title":"Toxic epidermal necrolysis with failure of re-epithelialization. Could umbilical cord mesenchymal stem cell transplantation have a role?","volume":"27","author":"Lehloenya","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000443164","article-title":"Facial scars following toxic epidermal necrolysis: role of adnexal involvement?","volume":"232","author":"Habre","year":"2016","journal-title":"Dermatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1213889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T07:14:30Z","timestamp":1697008470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1213889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":131,"alternative-id":["10.3389\/fmed.2023.1213889"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1213889","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"article-number":"1213889"}}